...
首页> 外文期刊>Mini reviews in medicinal chemistry >G-coupled protein receptors and breast cancer progression: potential drug targets.
【24h】

G-coupled protein receptors and breast cancer progression: potential drug targets.

机译:G偶联蛋白受体与乳腺癌的进展:潜在的药物靶标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Breast cancer remains a leading cause of death despite early screening and advances in medicine. Bone marrow metastasis often complicates the clinical picture by requiring more aggressive treatment and worsening long-term prognoses. Recent therapeutic targeting of hormonal receptors such as human epidermal growth factor receptor 2 and estrogen receptor has shown limited success in treating localized disease for those patients whose cancer cells are responsive. Although traditional approaches such as chemotherapy have demonstrated many successes, these agents fail to target quiescent cancer stem cells, which might have entered the bone marrow where they might be responsible for the quiescence population. Following years of clinical remission, these dormant cells could lead to secondary cancer resurgence. To date, little progress has been made in the development of targeted treatments for receptor negative and metastatic disease. In this review, we discuss the role of G-protein coupled receptors, including neurokinin-1, neurokinin-2 and chemokine receptor 4, as novel targets in the treatment of breast cancer.
机译:尽管早期筛查和医学进步,乳腺癌仍然是主要的死亡原因。骨髓转移通常需要更积极的治疗和长期预后恶化,从而使临床情况复杂化。激素受体(例如人表皮生长因子受体2和雌激素受体)的近期治疗靶点已显示出对癌细胞有反应的那些患者治疗局部疾病的成功有限。尽管诸如化学疗法之类的传统方法已显示出许多成功,但是这些药物无法靶向静止的癌症干细胞,而这些干细胞可能已经进入了骨髓,在那里它们可能导致静止的群体。经过多年的临床缓解,这些休眠细胞可能导致继发性癌症复发。迄今为止,在针对受体阴性和转移性疾病的靶向治疗的开发方面进展甚微。在这篇综述中,我们讨论了G蛋白偶联受体(包括神经激肽-1,神经激肽-2和趋化因子受体4)在乳腺癌治疗中的新靶点的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号